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Brief CommunicationCirculating FGF21 in humans is potently induced
by short term overfeeding of carbohydratesAnne-Marie Lundsgaard 1, Andreas M. Fritzen 1, Kim A. Sjøberg 1, Lene S. Myrmel 2, Lise Madsen 2,3,
Jørgen F.P. Wojtaszewski 1, Erik A. Richter 1, Bente Kiens 1,*ABSTRACT
Objective: Fibroblast-growth factor 21 (FGF21) is thought to be important in metabolic regulation. Recently, low protein diets have been shown to
increase circulating FGF21 levels. However, when energy contribution from dietary protein is lowered, other macronutrients, such as carbo-
hydrates, must be increased to meet eucaloric balance. This raises the possibility that intake of a diet rich in carbohydrates may induce an
increase in plasma FGF21 levels per se. Here we studied the role of dietary carbohydrates on the levels of circulating FGF21 and concomitant
physiologic effects by feeding healthy men a carbohydrate rich diet without reducing protein intake.
Methods: A diet enriched in carbohydrates (80 E% carbohydrate; CHO) and a eucaloric control diet (CON) were provided to nine healthy men for
three days. The energy intake during the CHO diet was increased (þ75% energy) to ensure similar dietary protein intake in CHO and CON. To
control for the effect of caloric surplus, we similarly overfed (þ75% energy) the same subjects for three days with a fat-rich diet (78 E% fat; FAT),
consisting of primarily unsaturated fatty acids. The three diets were provided in random order.
Results: After CHO, plasma FGF21 concentration increased 8-fold compared to CON (329 99 vs. 39 9 pg ml1, p< 0.05). In contrast, after
FAT only a non-signiﬁcant tendency (p ¼ 0.073) to an increase in plasma FGF21 concentration was found. The increase in FGF21 concentration
after CHO correlated closely (r ¼ 0.88, p < 0.01) with increased leg glucose uptake (62%, p < 0.05) and increased hepatic glucose production
(17%, p < 0.01), indicating increased glucose turnover. Plasma fatty acid (FA) concentration was decreased by 68% (p < 0.01), supported by
reduced subcutaneous adipose tissue HSL Ser660 phosphorylation (p< 0.01) and perilipin 1 protein content (p< 0.01), pointing to a suppression
of adipose tissue lipolysis. Concomitantly, a 146% increase in the plasma marker of hepatic de novo lipogenesis C16:1 n7 FA (p < 0.01) was
observed together with 101% increased plasma TG concentration (p < 0.001) in association with CHO intake and increased plasma FGF21
concentration.
Conclusion: Excess dietary carbohydrate, but not fat, led to markedly increased FGF21 secretion in humans, notably without protein restriction,
and affected glucose and lipid homeostais.
 2016 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The hormone ﬁbroblast growth factor 21 (FGF21) was early reported to
improve glucose homeostasis and to lower circulating triglycerides in
obese and insulin resistant mice [1] and later observed to be important
in the metabolic adaptations to fasting and ketosis [2,3]. Now, FGF21
has received increasing interest due to its role in the regulation of
energy homeostasis and its potential antidiabetic and lipid-lowering
properties [4,5]. Therefore, FGF21 holds promise as a therapeutic
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well as non-essential amino acids [11] has been shown to increase
plasma FGF21 levels. In humans, 28 days restriction of dietary protein
content to 6 E%, compared to 15 E% in the baseline diet, was shown to
increase plasma FGF21 concentration by 171% [12]. This was, how-
ever, under hypercaloric (þ39 E%) conditions resulting in a weight
gain (þ3.16 kg on average). Furthermore, the reduced protein was
compensated by increasing the fat intake from 25 to 52 E% and
decreasing the carbohydrate intake from 60 to 42 E% [13]. Thus, it is
not clear whether the increase in circulating FGF21 obtained in theof Science, University of Copenhagen, Copenhagen, Denmark 2National Institute of
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study by Laeger et al. resulted from protein restriction per se, alter-
ations in carbohydrate and fat intake, or as a result of the weight gain.
Our recent human study demonstrated that 7 days of a eucaloric
protein diluted diet (9.0 E% protein) increased plasma FGF21 con-
centration by 500% compared to a control diet with 20.2 E% dietary
protein [11]. Together, these ﬁndings have led to speculations that
dietary protein restriction induces FGF21 secretion and thereby en-
hances metabolic health [12,14].
Studies in rodents have also implied a role of carbohydrates in FGF21
induction. Hence, 12 h carbohydrate feeding (provided after 24 h of
fasting) was shown to induce FGF21 mRNA in rat liver [15]. Further-
more, monosaccharide-induced increases in FGF21 gene expression
in hepatocytes and mouse liver were mediated via the transcription
factor ChREBP [16e18]. This is supported by the observation that
FGF21 content in plasma was not increased in ChREBP knockout mice
in response to various sugars [19]. In addition, a recent study in mice,
providing 25 diets with varying macronutrient composition, showed an
additive effect of high-carbohydrate feeding to the induction of circu-
lating FGF21 with low-protein feeding [20]. Even though it has been
shown in humans that single monosaccharide intake brieﬂy increased
plasma FGF21 concentration [21], the role of dietary carbohydrates in
an ordinary diet (including mainly polysaccharides, but also di- and
monosaccharides) without protein restriction in humans is not known.
Despite reports demonstrating that starvation and ketogenic diets
induce FGF21 in mice, an increase in circulating FGF21 concentration
is not detected until after 7e10 days of starvation in humans [22,23],
and the reported effects of ketogenic diets are inconsistent [22,24].
Hence, in the context of dietary interventions the regulation of FGF21
may vary between mouse and man.
The aim of the present study was to evaluate the role of dietary car-
bohydrates in the regulation of circulating FGF21, without restricting
protein intake. We furthermore aimed to investigate whether a po-
tential dietary regulation of circulating FGF21 would have an impact on
glucose and lipid homeostasis in humans. For this purpose, we per-
formed a highly controlled randomized three day cross-over dietary
intervention study in healthy men. In order to maximize substrate
provision and hence metabolic ﬂux, in particular to the liver but also in
peripheral tissues, and even more importantly to avoid a decrease in
protein intake, the carbohydrate-rich diet was provided in excess of
eucaloric energy requirements. To control for the effect of caloric
excess, subjects also ingested a similar hypercaloric fat-rich diet in
which fat consisted primarily of unsaturated fatty acids.
2. METHODS
2.1. Subjects and diets
Nine men were recruited for the study, which was approved by the
Copenhagen Ethics Committee (KF 01 261127) and performed in
accordance with the Declaration of Helsinki. Informed written consent
was received from each participant prior to study inclusion. All subjects
were healthy, moderately physically active, and with no family history
of diabetes. This study is part of a larger project aiming at elucidating
the effects of different types of diets on metabolism in nine male
volunteers (unpublished). In the present study, these subjects ingested
a hypercaloric carbohydrate-rich diet (CHO) (80 E% carbohydrate, 11 E
% protein, 9 E% fat) and a eucaloric control diet (CON) (62 E% car-
bohydrates, 14 E% protein, 24 E% fat), reﬂecting their habitual diet. A
hypercaloric high-fat diet, consisting primarily of unsaturated FA (FAT)
(10 E% carbohydrate, 12 E% protein, 78 E% fat) was also provided in
order to serve as control for the caloric excess. The macronutrient
composition of CHO, FAT, and CON are summarized in SupplementalMOLECULAR METABOLISM 6 (2017) 22e29  2016 The Authors. Published by Elsevier GmbH. This is an open
www.molecularmetabolism.comTable S1. All diets were provided for three days in a randomized
cross-over design, with each intervention separated by at least three
weeks. Before each three-day intervention, all subjects consumed the
eucaloric control diet for 5 days to ensure the same conditions before
each intervention. All food items were weighed and prepared in the
metabolic kitchen. The daily menus were delivered to the subject, who
ingested them at home. The CHO diet consisted of carbohydrate-rich
food items as bread, pasta, cereals, corn, jam, and juice, with high
to moderate glycemic index. The diet was mainly comprised of poly-
saccharides, with 19% reﬁned sugar and the ratio between glucose
and fructose was 1:1 (Supplemental Table S3 and S4). In the FAT diet,
mono- and polyunsaturated fatty acids both comprised 34 E%
(Supplemental Table S1).
To evaluate the training status of the participants, maximal oxygen
uptake was measured by an incremental exercise test on a Monark
Ergomedic 839E bicycle ergometer (Monark, Sweden). Body
composition and leg mass (LM) were determined using dual-energy
X-ray absorptiometry (Lunar DPX-IQ DEXA Scanner, Lunar Corpora-
tion, USA) after 4 h of fasting. The nine male subjects were 23  3
(mean  SD) years old, with a body mass index (BMI) of
23.7  1.7 kg m2 and maximal oxygen uptake (VO2peak) of
52  4 ml kg1 min1.
The daily energy requirements were individually determined from
weighed dietary registrations and calculations of energy requirements
(WHO/FAO/UNU). The three days CHO and FAT diets were provided in
excess of eucaloric energy requirements, with a þ75% increase in
daily energy intake. Hence, the subjects ingested 13.7  0.2 MJ
during the CON diet and according to the hypercaloric energy provision
24.0  0.4 MJ during the experimental diets (Table S1).
2.2. Experimental protocol
After three days on the experimental diets or the control diet, subjects
ingested a light standardized breakfast (1.6 MJ) at 5 A.M at home
(Supplemental Table S5). Subjects arrived at the institute at 7.30 A.M,
and, after a period of supine rest, teﬂon catheters were inserted in the
femoral artery and vein under local anesthesia. Then, a [6,6-2H2]
glucose tracer infusion (0.055 mg kg1 min1) was administered in
order to measure hepatic glucose production. The infusion was initi-
ated by a bolus injection of [6,6-2H2] glucose (3.203 mg kg
1). After
120 min, blood samples were obtained from the femoral artery and
vein. Femoral arterial blood ﬂow was determined simultaneously with
the arterio-venous blood sampling by a laser ultra-sound Doppler
technique (Philips iU22, ViCare Medical, Denmark) [25]. In order to
study molecular metabolism in adipose tissue, biopsies were obtained
from the subcutaneous periumbilical adipose tissue, immediately
frozen in liquid nitrogen and stored at 80 C. All blood and tissue
samples were collected 6 h after the breakfast meal, when subjects
were in the post-absorptive state.
2.3. Plasma analyses
Plasma glucose concentration was measured on an ABL615 (Radi-
ometer Medical A/S, Denmark), and insulin concentration was
measured by an enzyme-linked immunosorbent assay (ELISA)
(ALPCO, USA). The plasma concentrations of FA (NEFA C kit, Wako
Chemicals GmbH, Germany) and triacylglycerol (TG) (GPO-PAP kit,
Roche Diagnostics, Germany) were measured using enzymatic
colorimetric methods (Hitachi 912 automatic analyzer, Boehringer,
Germany). Plasma cholesterol concentration was measured by a
ﬂuorometric method (Roche Diagnostics, Germany). Plasma
epinephrine and norepinephrine concentrations were determined by
radioimmunoassay (2-CAT 125I RIA kit, Labor Diagnostika, Germany).access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 23
Figure 1: Effect of the dietary interventions on arterial plasma FGF21 concentration.
Data are means  SEM. Paired t-tests were used. CON: eucaloric control diet, CHO:
hypercaloric carbohydrate-rich diet, FAT: hypercaloric high-fat diet. *p < 0.05
compared with CON. n ¼ 9, one subject did not complete the CHO trial, hence n ¼ 8 in
CHO. Data were obtained in the post-absorbtive state 6 h after a small 1.6 MJ breakfast
(5 A.M).
Brief CommunicationPlasma adiponectin concentration was measured on an AutoDELFIA
(Perkin Elmer, USA) automated analyzer. Plasma FGF21 concentration
was measured by ELISA (FGF21 Quantikine ELISA kit, R&D Systems,
USA), in which the standard curve range for the assay was 10e
2000 pg ml1. FGF21 was analyzed in both arterial and venous
plasma, with no difference obtained in FGF21 concentration. Plasma
enrichments of the stable glucose isotope were measured using liquid
chromatography mass spectrometry (ThermoQuest Finnegan AQA,
USA) as previously described [26]. For analysis of palmitoleic acid
concentration in plasma, lipids were extracted using chloroform/
methanol (2:1, v/v) and ﬁltered prior to saponiﬁcation and methylation
using 12% BF3 in methanol. Methylated FA were separated as
described in detail elsewhere [27]. The respective FA species were
identiﬁed by retention time using standard mixtures of methyl esters
(Nu-Chek, USA).
2.4. Western blotting
Samples of subcutaneous adipose tissue were homogenized (Tissue
Lyzer II, Qiagen, Germany) in ice-cold buffer as described previously
[28]. Homogenates were rotated end-over-end for one hour, and lysate
supernatants were collected by centrifuging 20 min at 16,000 g at
4 C. The upper fat layer was carefully removed before the lysate
supernatant was collected. Protein concentrations were determined in
triplicates using the bicinchoninic acid (BCA) method (Pierce
Biotechnology BCA, USA). Samples were heated (96 C) in Laemmli
buffer before subjected to SDS-PAGE and semi-dry blotting. The pri-
mary antibodies used are described in Supplemental Table S2. Sec-
ondary antibodies were from Dako Cymation (Denmark). Membranes
were probed with enhanced chemiluminescence (ECLþ; Amersham
Biosciences, USA), and immune complexes were visualized using
BioRad ChemiDoc MP Imaging System (Hercules, USA). Signals
were quantiﬁed (Image Lab, Life Sciences, USA) and expressed as
arbitrary units.
2.5. Calculations
Leg glucose uptake was calculated as the arterial-venous difference
multiplied by blood ﬂow in accordance with Fick’s principle and related
to leg mass (LM). Glucose rate of appearance (Ra) was calculated from
the last 30 min of the 120 min tracer infusion period using Steele’s
steady state equations [29].
2.6. Statistical analyses
All data are expressed as means  SEM, except characteristics of the
subjects (means  SD). Data from each experimental trial were
compared to the control trial by paired t-tests, to test for effect of the
respective experimental diets. The strength of association between
parameters was analyzed using Pearson correlation analysis.
3. RESULTS AND DISCUSSION
3.1. Dietary carbohydrate but not caloric excess increases
circulating FGF21
Here we demonstrate in healthy male volunteers that three days
consumption of a hypercaloric carbohydrate-rich diet (80 E%)
increased the plasma FGF21 concentration 803% compared with CON
(p< 0.05) (Figure 1). In contrast, the concentration of FGF21 in plasma
only tended (p ¼ 0.073) to be increased after three days consumption
of a hypercaloric unsaturated high-fat diet (78 E% fat) (Figure 1). These
data underscore that dietary carbohydrates potently induce FGF21
during conditions of non-restricted protein intake, highlighting a novel
and important effect of dietary carbohydrates in the regulation of24 MOLECULAR METABOLISM 6 (2017) 22e29  2016 The Authors. Published by Elsevier GmbH. Thiscirculating FGF21 in humans. The fact that the FAT diet did not
appreciably increase plasma FGF21 concentration indicates that
caloric excess per se does not induce FGF21 secretion.
In mice, FGF21 mRNA is reported to be predominantly expressed in
pancreas and liver [30], with markedly lower FGF21 mRNA levels
present in human skeletal muscle [31,32] and subcutaneous and
visceral adipose tissue [6,33]. Elevated circulating levels of FGF21 in
mice and humans have mainly been linked to increased FGF21 syn-
thesis in the liver [34,35]. Thus, the observed increase in plasma
FGF21 concentration in the present human study was likely related to
induction of FGF21 in the liver.
3.2. Lipid and glucose homeostasis in the context of excess
carbohydrate intake and FGF21 induction
Next we aimed to investigate the metabolic effects of the CHO diet and
whether the dietary upregulation of circulating FGF21 was associated
with changes in glucose and lipid homeostasis.
After CHO, the plasma TG concentration was increased by 101%
compared with CON (p < 0.001) (Figure 2A) at the same time as the
plasma FA concentration was decreased by 68% (Figure 2B). Hence,
the increase in plasma TG concentration does not seem to be
ascribed to increased hepatic FA supply from plasma. It has been
shown in another study in healthy men that 4 days hypercaloric
provision of carbohydrates (enterally) increases VLDL-TG secretion
rate markedly, in part due to increased secretion of de novo syn-
thesized FA in the liver [36]. Extending these observations to the
present study, the obtained increase in plasma TG concentration
likely reﬂected increased VLDL-TG secretion after the several days of
high carbohydrate intake. Along this line, we observed a 146% in-
crease in plasma C16:1 FA concentration after CHO (Figure 2C), a
marker of de novo lipogenesis [37], indicating an increased hepatic
de novo lipogenesis. Interestingly, positive correlations were
observed between the increase in plasma FGF21 concentration afteris an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 2: Systemic and peripheral lipid and glucose homeostasis after the control diet (CON) and the carbohydrate-rich diet (CHO). A. Arterial plasma triacylglycerol (TG) con-
centration. B. Arterial fatty acid (FA) concentration. C. Arterial palmitoleic acid concentration. D. Hepatic glucose rate of appearance (Ra). E. Leg glucose uptake expressed per kg
leg mass (LM). F þ G. Scatter plots illustrating the associations between the change in plasma FGF21 (F) or plasma insulin (G) after CHO and the change in leg glucose uptake.
Data are means  SEM. Paired t-tests were used in AeE. Pearsons correlation analysis was applied in F þ G. *p < 0.05, **p < 0.01, ***p < 0.001 compared with CON. n ¼ 9 in
CON, one subject did not complete the CHO trial, hence n ¼ 8 in CHO. Data were obtained in the post-absorptive state 6 h after a small 1.6 MJ breakfast (5 A.M).
Table 1 e Arterial plasma parameters. Data are means  SEM and
obtained in the late post-absorptive state 6 h after a small 1.6 MJ breakfast.
*p < 0.05, **p < 0.01 compared to CON. n ¼ 9 in CON and n ¼ 8 in CHO.
Paired t-tests were applied to test for effect of the CHO diet.
Arterial plasma parameters CON CHO
Glucose, mmol l1 5.7  0.1 5.6  0.0
Insulin, mU ml1 5.0  0.9 7.9  1.4*
Epinephrine, nmol l1 0.3  0.1 0.2  0.1
Norepinephrine, nmol l1 1.3  0.5 1.6  0.6
Adiponectin, mg ml1 7.1  1.5 7.4  1.1
Total cholesterol, mmol l1 4.2  0.3 3.6  0.2**
HDL-cholesterol, mmol l1 1.2  0.1 1.1  0.1*
LDL-cholesterol, mmol l1 2.4  0.3 1.8  0.2**CHO and the increase in C16:1 n7 (r ¼ 0.79, p < 0.05) and the
increase in plasma TG (r ¼ 0.70, p < 0.05). Together these ﬁndings
suggest that the carbohydrate load from the CHO diet caused sub-
stantial de novo lipogenesis in the liver. This may contribute to the
observed increase in FGF21 secretion, as cross-sectional studies
have demonstrated that plasma FGF21 concentration is positively
associated with intrahepatic lipid content [24,38,39], which is
further associated with VLDL-TG secretion rate in healthy subjects
[40], thus supporting a relationship between hepatic lipid synthesis
and FGF21 secretion. Notably, we observed that total cholesterol
(p < 0.01) and LDL-cholesterol (p < 0.01) concentrations in plasma
were reduced (Table 1), indicating an improved lipoprotein proﬁle
even in the face of the increase in plasma TG concentrations
approaching mild hypertriglyceridemia. This is in line with the
observation of reduced plasma LDL-cholesterol concentrations in
obese humans after FGF21 administration [41].
After CHO, hepatic glucose production was increased by 17%
compared with CON (p < 0.01) (Figure 2D), despite slightly increased
plasma insulin levels (p < 0.05) (Table 1). The increase in plasma
FGF21 after CHO was positively correlated to the increase in hepatic
glucose production (r ¼ 0.71, p < 0.05), suggesting a link between
FGF21 and hepatic glucoregulation. Our data are supported by ﬁndings
in mice, in which 8 days administration of FGF21 increased basal
hepatic glucose production [42].MOLECULAR METABOLISM 6 (2017) 22e29  2016 The Authors. Published by Elsevier GmbH. This is an open
www.molecularmetabolism.comNotably, after CHO the increase in circulating FGF21 was accompanied
by a 62% increase in leg glucose uptake compared to CON (p < 0.05)
(Figure 2E). This increase in leg glucose uptake was strongly correlated
to the increase in plasma FGF21 concentration (r ¼ 0.88, p < 0.01)
(Figure 2F). This may imply that FGF21 has direct effects on muscle
glucose uptake, in agreement with FGF21 treatment increasing basal
glucose uptake in human myotubes [43]. Concomitantly, a small in-
crease in plasma insulin concentration after CHO compared to CONaccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 25
Brief Communicationwas obtained (7.9  1.4 versus 5.0  0.9 mU ml1, Table 1), which
was also correlated to the increase in leg glucose uptake (r ¼ 0.82,
p < 0.05) (Figure 2G). The plasma insulin concentration reported to
half-maximally stimulate leg glucose uptake isw50 mU ml1 [44,45].
Thus, it can be questioned to what extent the 2.9 mU ml1 increase in
plasma insulin, with insulin levels on the lower ﬂat part of the dose-
response curve, was responsible for the signiﬁcant increase in leg
glucose uptake after the CHO diet. However, it is possible that the
apparent effect of insulin on leg glucose uptake is due to potentiation of
the insulin effect by FGF21, as FGF21 has been shown to potentiate the
effect of insulin on glucose uptake in human myotubes and mouse
muscle [43]. Notably, when the absolute plasma concentrations of
FGF21 and insulin after the CHO diet were correlated with leg glucose
uptake, in contrast to the delta-values when compared to CON in
Figure 2F, G, the plasma FGF21 concentration correlated closely with
leg glucose uptake (r ¼ 0.9, p < 0.01), while plasma insulin did not
(r¼ 0.45, p¼ 0.265) (Supplemental Figure S1). This may suggest that
FGF21 rather than insulin is the major regulator of the increase in leg
glucose uptake observed in the present study.Figure 3: Molecular metabolism in subcutaneous adipose tissue after the control (CON)
phorylation. B. HSL protein content. C. Adipose triglyceride lipase (ATGL) protein content
phorylation. F. AMPKa1 protein content. G. Representative blots. Data are means  SEM.
subject did not complete the CHO trial, hence n ¼ 8 in CHO. Data were obtained in the
26 MOLECULAR METABOLISM 6 (2017) 22e29  2016 The Authors. Published by Elsevier GmbH. ThisFGF21 has also been suggested to regulate basal glucose uptake in
human adipocytes [1], 3T3-L1 adipocytes [46] and mouse adipose
tissue [47] via an adiponectin-AMPK dependent pathway [48,49].
However, the present data provide no indications of an adiponectin-
AMPK axis activated in human adipose tissue in response to
increased circulating FGF21 (Table 1 and Figure 3EeF).
In the present study, the subjects consumed a small and identical
breakfast meal after CON and CHO (Supplemental Table S5) 6 h before
blood sampling to ensure a similar post-absorptive state. It has been
shown in healthy humans that oral administration of monosaccharides
in the form of 75 g fructose or glucose acutely increase plasma FGF21
[21]. 75 g fructose increased FGF21 levels by 3.4 fold at 2 h, whereas
75 g glucose induced a more modest 2-fold increase in plasma FGF21
after 3 h. However, in both situations plasma FGF21 levels were back
to baseline after approximately 4 h [21]. Considering the transient
character of the acute glucose- and fructose-induced increases in
circulating FGF21 [21] and that the half-life of recombinant human
FGF21 is 1e2 h [46,50], it is likely that the substantial 8-fold increase
in plasma FGF21 concentration obtained in the post-absorptive state inand the carbohydrate-rich diet (CHO). A. Hormone-sensitive lipase (HSL) Ser660 phos-
. D. Perilipin 1 protein content. E. AMP-activated protein kinase (AMPK) Thr172 phos-
Paired t-tests were used in AeF. **p < 0.01 compared with CON. n ¼ 9 in CON, one
post absorptive state 6 h after a small 1.6 MJ breakfast (5 A.M).
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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CHO originates from a more persistent secretory regulation. Thus, this
study shows the impact of carbohydrate-rich food items, occurring in a
normal habitual diet, on FGF21 regulation in humans. Interestingly,
genome-wide association studies in human cohorts have shown an
association between SNPs related to the FGF21 locus and carbohy-
drate intake [51,52]. A link between FGF21 and dietary carbohydrate
consumption is further supported by studies in mice and monkeys,
which show that FGF21 knockout increases preference for mono- and
disaccharide intake. Moreover, FGF21 overexpression or administra-
tion of FGF21 analogs decrease the preference for mono- and di-
saccharides and artiﬁcial sweeteners, with no apparent effect on fat or
protein intake [19,53]. Whether the observed higher plasma FGF21
levels after the CHO diet in the present study affected food preference
is a possibility, but was not directly evaluated.
3.3. Inhibition of adipose tissue lipolysis
Three days of FGF21 treatment has been reported to inhibit lipolysis in
human adipocytes [54]. Supporting these ﬁndings, the increased
plasma FGF21 concentration was observed at the same time as
plasma FA concentration was markedly decreased in the present study
after CHO. We observed in subcutaneous adipose tissue that phos-
phorylation of the activating Ser660 site on hormone sensitive lipase
(HSL) was decreased by 47% (p < 0.01) (Figure 3A) and that the
protein content of perilipin 1 was decreased by 29% after CHO
(p < 0.01) (Figure 3D). Perilipin 1 is a key regulator of both basal and
protein kinase A (PKA)-stimulated lipolysis in adipose tissue, and since
HSL translocation to the lipid droplets requires a functional perilipin 1
[55] and perilipin 1 activation is required to stimulate HSL-mediated
lipolysis [56], these molecular data collectively support that adipose
tissue lipolysis was lowered after CHO. Consistent with our observa-
tions, Arner et al. found that the FGF21-induced inhibition of lipolysis in
the human primary adipocytes was accompanied by a reduced peril-
ipin 1 protein content [54].
In summary, in humans we here employed a dietary strategy by which
the effect of short term overfeeding of carbohydrates revealed a
paramount and remarkable stimulating effect on FGF21 secretion,
without reduction in the dietary protein content. In contrast, energy
excess per se, induced by a hypercaloric fat-rich diet, did not induce a
detectable increase in circulating FGF21. Dietary carbohydrate excess
led to differential responses in the liver and peripheral tissues. The
increase in circulating FGF21 after high carbohydrate intake was
associated with indices of increased hepatic lipogenesis and glucose
production, and this was observed concomitantly with increased pe-
ripheral glucose disposal, with a close correlation between the in-
crease in plasma FGF21 concentration and increased leg glucose
uptake. This suggests that FGF21 secretion provided a mechanism for
peripheral disposal of the carbohydrate load. Furthermore, the FGF21-
mediated suppression of adipose tissue lipolysis could be a mecha-
nism to suppress hepatic FA supply under conditions of increased de
novo lipogenesis. Accordingly, we here demonstrate an important role
of dietary carbohydrates in the regulation of human FGF21 secretion,
and our data further point to effects of FGF21 in human glucose and
lipid homeostasis.
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